GPCR19

GPCR19製品

All (11)
GPCR19活性剤(2)
GPCR19拮抗剤(1)
GPCR19作動薬(4)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S6806	SBI-115	SBI-115 is a novel TGR5 (GPCR19) antagonist. SBI-115 decreases cell proliferation, cholangiocyte spheroid growth and cAMP levels in cystic cholangiocytes.	Cells, 2023, 12(4)526 Nat Commun, 2022, 13(1):3419 Research Square, 2021, 10.21203/rs.3.rs-274411/v1
S4689	Deoxycholic acid	Deoxycholic acid (Deoxycholate, Desoxycholic acid, Cholerebic, Cholorebic) is a cytolytic agent. The physiologic effect of deoxycholic acid is by means of decreased cell membrane integrity.	Bio Protoc, 2022, 12(20)e4533
S0193	TGR5 Receptor Agonist	TGR5 Receptor Agonist (TGR5, CCDC, MDK00245, compd 6) is a potent agonist of TGR5(GPCR19, GPBAR1, M-BAR). TGR5 Receptor Agonist shows improved potency with pEC50 of 6.8 and 7.5 in the U2-OS cell assay and in melanophore cells, respectively.	Research Square, 2021, 10.21203/rs.3.rs-274411/v1
S0034	BAR501	BAR501 is a potent and selective G protein-coupled bile acid receptor 1 (GPBAR1, GPCR19, TGR5) agonist that effectively transactivates GPBAR1 in HEK293 cells overexpressing a CRE along with GPBAR1 with EC50 of 1 μM.
S2311	Hyodeoxycholic acid (HDCA)	Hyodeoxycholic (HDCA, NSC 60672) acid is a secondary bile acid, one of the metabolic byproducts of intestinal bacteria.
S3069	Deoxycholic acid sodium salt	Deoxycholic acid sodium salt (Sodium Deoxycholate, Sodium Desoxycholate, Cholanoic Acid, ATX-101, Kythera, Belkyra, DCA) is specifically responsible for activating the TGR5 receptor (GPCR19) that stimulates brown adipose tissue (BAT) thermogenic activity.
S6741	SB-756050	SB-756050 is a selective TGR5 agonist (EC50 = 1.3 μM for the human receptor).
S0193	TGR5 Receptor Agonist	TGR5 Receptor Agonist (TGR5, CCDC, MDK00245, compd 6) is a potent agonist of TGR5(GPCR19, GPBAR1, M-BAR). TGR5 Receptor Agonist shows improved potency with pEC50 of 6.8 and 7.5 in the U2-OS cell assay and in melanophore cells, respectively.	Research Square, 2021, 10.21203/rs.3.rs-274411/v1
S0034	BAR501	BAR501 is a potent and selective G protein-coupled bile acid receptor 1 (GPBAR1, GPCR19, TGR5) agonist that effectively transactivates GPBAR1 in HEK293 cells overexpressing a CRE along with GPBAR1 with EC50 of 1 μM.
S2311	Hyodeoxycholic acid (HDCA)	Hyodeoxycholic (HDCA, NSC 60672) acid is a secondary bile acid, one of the metabolic byproducts of intestinal bacteria.
S6741	SB-756050	SB-756050 is a selective TGR5 agonist (EC50 = 1.3 μM for the human receptor).
S4689	Deoxycholic acid	Deoxycholic acid (Deoxycholate, Desoxycholic acid, Cholerebic, Cholorebic) is a cytolytic agent. The physiologic effect of deoxycholic acid is by means of decreased cell membrane integrity.	Bio Protoc, 2022, 12(20)e4533
S3069	Deoxycholic acid sodium salt	Deoxycholic acid sodium salt (Sodium Deoxycholate, Sodium Desoxycholate, Cholanoic Acid, ATX-101, Kythera, Belkyra, DCA) is specifically responsible for activating the TGR5 receptor (GPCR19) that stimulates brown adipose tissue (BAT) thermogenic activity.
S6806	SBI-115	SBI-115 is a novel TGR5 (GPCR19) antagonist. SBI-115 decreases cell proliferation, cholangiocyte spheroid growth and cAMP levels in cystic cholangiocytes.	Cells, 2023, 12(4)526 Nat Commun, 2022, 13(1):3419 Research Square, 2021, 10.21203/rs.3.rs-274411/v1
S0193	TGR5 Receptor Agonist	TGR5 Receptor Agonist (TGR5, CCDC, MDK00245, compd 6) is a potent agonist of TGR5(GPCR19, GPBAR1, M-BAR). TGR5 Receptor Agonist shows improved potency with pEC50 of 6.8 and 7.5 in the U2-OS cell assay and in melanophore cells, respectively.	Research Square, 2021, 10.21203/rs.3.rs-274411/v1
S0034	BAR501	BAR501 is a potent and selective G protein-coupled bile acid receptor 1 (GPBAR1, GPCR19, TGR5) agonist that effectively transactivates GPBAR1 in HEK293 cells overexpressing a CRE along with GPBAR1 with EC50 of 1 μM.
S2311	Hyodeoxycholic acid (HDCA)	Hyodeoxycholic (HDCA, NSC 60672) acid is a secondary bile acid, one of the metabolic byproducts of intestinal bacteria.
S6741	SB-756050	SB-756050 is a selective TGR5 agonist (EC50 = 1.3 μM for the human receptor).

GPCR19阻害剤の選択性比較